Metformin Recall 2021: More Diabetes Medication Pulled Over Cancer Risks

Following several drugmakers’ recalls for the diabetes medication Metformin throughout 2020 and 2021 over cancer concerns, Viona Pharmaceuticals has recalled 33 lots of Metformin Hydrochloride Extended-Release Tablets in 750 mg dosages due to a potential cancer risk.

The diabetes drug, which was manufactured by Cadila Healthcare Limited in Ahmedabad, India, has N-nitrosodimethylamine – a probable human carcinogen that could cause cancer – in levels that are higher than acceptable by the Food and Drug Administration.

Metformin is used for managing blood glucose in adults with Type 2 diabetes mellitus.

The recalled diabetes medication was packaged in HDPE bottles of 100 tablets under the NCD 72578-036-01. The Metformin drug can be identified as a white to an off-white, capsule-shaped, uncoated tablet that is debossed with a “Z” and“C” on one side and “20” on the other side.

The affected Metformin was distributed nationwide and has expiration dates ranging from June 2022 to March 2023.

A full list of the 33 lots of Metformin tablets affected by the recall can be viewed here.

Patients who have the affected Metformin tablets in their possession are advised to continue taking the medication as stopping the drug without talking to a healthcare provider first could be dangerous, the FDA said. A physician should be consulted for an alternative treatment plan.

Questions about the recall can be directed to Eversana Life Science Services at 1-888-304-5033, option 1, Monday through Friday from 8 a.m. to 7 p.m. CT.

Patients who have problems related to taking or using the recalled medication should contact their healthcare provider.

Viona Pharmaceuticals and Cadila Healthcare Limited said they have not received any reports of adverse events related to the recalled medication.